Амантонио – Прививать или не прививать? или Ну, подумаешь, укол! Мифы о вакцинации (страница 16)
5.
Fredericks DN et al. Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates.
6.
Daling JR et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors.
7.
Haverkos H et al. The cause of invasive cervical cancer could be multifactorial.
8.
Ostör AG. Natural history of cervical intraepithelial neoplasia: a critical review.
9.
Tomljenovic L et al. Human papillomavirus (HPV) vaccines as an option for preventing cervical malignancies: (how) effective and safe?
10.
Hildesheim A et al. Risk factors for rapid-onset cervical cancer.
11.
Mahmud SM et al. Effectiveness of the quadrivalent human papillomavirus vaccine against cervical dysplasia in Manitoba, Canada.
12.
Tomljenovic L et al. Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil.
13.
Tomljenovic L et al. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?
14.
Inbar R et al. Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil.
15.
Geier DA et al. A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.
16.
Rodríguez-Galán MA et al. Adverse reactions to human papillomavirus vaccine in the Valencian Community (2007-2011).
17.
Geier DA et al. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
18.
Liu XC et al. Adverse events following HPV vaccination, Alberta 2006-2014.
19.
Markowitz LE et al. Prevalence of HPV After Introduction of the Vaccination Program in the United States.
20.
Fischer S et al. Shift in prevalence of HPV types in cervical cytology specimens in the era of HPV vaccination.
21.
Giambi C et al. A cross-sectional study to estimate high-risk human papillomavirus prevalence and type distribution in Italian women aged 18-26 years.
22.
Mollers M et al. Population- and type-specific clustering of multiple HPV types across diverse risk populations in the Netherlands.
23.
Guo F et al. Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).
24.
Peter C Gøtzsche. Complaint to the European Medicines Agency (EMA) over maladministration at the EMA.
25.
Brinth LS et al. Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus.
26.
Brinth L et al. Suspected side effects to the quadrivalent human papilloma vaccine.
27.
Palmieri B et al. Severe somatoform and dysautonomic syndromes after HPV vaccination: case series and review of literature.
28.
Kinoshita T et al. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine.
29.
Blitshteyn S. Postural tachycardia syndrome following human papillomavirus vaccination.
30.
Shaw LTC. Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental?
31.
Little DT et al. Adolescent premature ovarian insufficiency following human papillomavirus vaccination: a case series seen in general practice.
32.
DeLong G. A lowered probability of pregnancy in females in the USA aged 25-29 who received a human papillomavirus vaccine injection.
33.
McInerney KA et al. the effect of vaccination against human papillomavirus on fecundability.
34.
Gajdová M et al. Delayed effects of neonatal exposure to Tween 80 on female reproductive organs in rats.
35.
Azmin MN et al. The distribution and elimination of methotrexate in mouse blood and brain after concurrent administration of polysorbate 80.
36.
Pardridge WM. The blood-brain barrier: bottleneck in brain drug development.
37.